Henshaw Capital’s Dr. Reddy's Laboratories RDY Stock Holding History

Henshaw Capital’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-23,640	Closed	-$309K	–	331
2021 Q4	$309K	Hold	23,640	–	–	0.02%	259
2021 Q3	$308K	Sell	23,640 -39,340	-62%	-$524K	0.02%	253
2021 Q2	$926K	Buy	62,980 +10,510	+20%	+$147K	0.06%	114
2021 Q1	$644K	Buy	52,470 +4,280	+9%	+$55K	0.04%	140
2020 Q4	$687K	Sell	48,190 -5,010	-9%	-$67.5K	0.05%	129
2020 Q3	$740K	Buy	53,200 +10,020	+23%	+$119K	0.06%	120
2020 Q2	$458K	Sell	43,180 -4,335	-9%	-$44.1K	0.04%	154
2020 Q1	$383K	Buy	47,515 +11,195	+31%	+$93.3K	0.04%	168
2019 Q4	$295K	Hold	36,320	–	–	0.02%	202
2019 Q3	$275K	Hold	36,320	–	–	0.02%	216
2019 Q2	$272K	Buy	+36,320	New	+$286K	0.02%	218
2017 Q2	–	Sell	-25,160	Closed	-$202K	–	317
2017 Q1	$202K	Hold	25,160	–	–	0.02%	269
2016 Q4	$228K	Hold	25,160	–	–	0.03%	253
2016 Q3	$234K	Buy	25,160 +765	+3%	+$7.3K	0.03%	246
2016 Q2	$250K	Hold	24,395	–	–	0.03%	228
2016 Q1	$220K	Buy	+24,395	New	+$218K	0.03%	242

Other funds holding RDY

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Henshaw Capital's RDY Position: Q1 2022 in Review

Henshaw Capital sold out of Dr. Reddy's Laboratories (RDY) in Q1 2022, closing a stake of 23,640 shares — an estimated $309K sold.

Henshaw Capital first reported a position in RDY in Q1 2016 and held it in 16 quarters. The position peaked at $926K in Q2 2021. 146 funds tracked by Wall St. Rank hold RDY as of Q1 2022.

Henshaw Capital reported no remaining Dr. Reddy's Laboratories position as of Q1 2022 after selling out during the quarter.
Henshaw Capital sold 23,640 Dr. Reddy's Laboratories shares in Q1 2022, an estimated $309K.
Henshaw Capital first reported a position in Dr. Reddy's Laboratories in Q1 2016 and held it in 16 quarters.
Henshaw Capital's Dr. Reddy's Laboratories position peaked at $926K in Q2 2021.
146 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2022.

Based on Henshaw Capital's 13F filing for Q1 2022, filed 28 May 2026.